Literature DB >> 15286781

Regulatory T cells and mechanisms of immune system control.

Anne O'Garra1, Paulo Vieira.   

Abstract

The immune system evolved to protect the host against the attack of foreign, potentially pathogenic, microorganisms. It does so by recognizing antigens expressed by those microorganisms and mounting an immune response against all cells expressing them, with the ultimate aim of their elimination. Various mechanisms have been reported to control and regulate the immune system to prevent or minimize reactivity to self-antigens or an overexuberant response to a pathogen, both of which can result in damage to the host. Deletion of autoreactive cells during T- and B-cell development allows the immune system to be tolerant of most self-antigens. Peripheral tolerance to self was suggested several years ago to result from the induction of anergy in peripheral self-reactive lymphocytes. More recently, however, it has become clear that avoidance of damage to the host is also achieved by active suppression mediated by regulatory T (T(reg)) cell populations. We discuss here the varied mechanisms used by T(reg) cells to suppress the immune system.

Mesh:

Substances:

Year:  2004        PMID: 15286781     DOI: 10.1038/nm0804-801

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  214 in total

1.  IL-2 and IL-4 stimulate MEK1 expression and contribute to T cell resistance against suppression by TGF-beta and IL-10 in asthma.

Authors:  Qiaoling Liang; Lei Guo; Shaila Gogate; Zunayet Karim; Arezoo Hanifi; Donald Y Leung; Magdalena M Gorska; Rafeul Alam
Journal:  J Immunol       Date:  2010-10-06       Impact factor: 5.422

2.  CD46 engagement on human CD4+ T cells produces T regulatory type 1-like regulation of antimycobacterial T cell responses.

Authors:  Steven M Truscott; Getahun Abate; Jeffrey D Price; Claudia Kemper; John P Atkinson; Daniel F Hoft
Journal:  Infect Immun       Date:  2010-10-04       Impact factor: 3.441

3.  Regulatory potential and control of Foxp3 expression in newborn CD4+ T cells.

Authors:  Helene C Dujardin; Odile Burlen-Defranoux; Laurent Boucontet; Paulo Vieira; Ana Cumano; Antonio Bandeira
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-27       Impact factor: 11.205

Review 4.  IL-10-producing and naturally occurring CD4+ Tregs: limiting collateral damage.

Authors:  Anne O'Garra; Pedro L Vieira; Paulo Vieira; Anne E Goldfeld
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

5.  Identification of a unique double-negative regulatory T-cell population.

Authors:  Byung O Lee; Joyce E Jones; Cory J Peters; David Whitacre; Lars Frelin; Janice Hughes; Won-Keun Kim; David R Milich
Journal:  Immunology       Date:  2011-12       Impact factor: 7.397

Review 6.  Immune modulation of inflammatory conditions: regulatory T cells for treatment of GvHD.

Authors:  Doreen Haase; Mireille Starke; Kia Joo Puan; Tuck Siong Lai; Olaf Rotzschke
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

Review 7.  Immunogenomics and systems biology of vaccines.

Authors:  Luigi Buonaguro; Bali Pulendran
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

8.  Level, phenotype and activation status of CD4+FoxP3+ regulatory T cells in patients chronically infected with human immunodeficiency virus and/or hepatitis C virus.

Authors:  N I Rallón; M López; V Soriano; J García-Samaniego; M Romero; P Labarga; P García-Gasco; J González-Lahoz; J M Benito
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

9.  IL-21 mediates suppressive effects via its induction of IL-10.

Authors:  Rosanne Spolski; Hyoung-Pyo Kim; Wei Zhu; David E Levy; Warren J Leonard
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

10.  Parasitic infection as a potential therapeutic tool against rheumatoid arthritis.

Authors:  Shadike Apaer; Tuerhongjiang Tuxun; Hai-Zhang Ma; Heng Zhang; Amina Aierken; Abudusalamu Aini; Yu-Peng Li; Ren-Yong Lin; Hao Wen
Journal:  Exp Ther Med       Date:  2016-09-05       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.